title: Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
abstract: An observational study was conducted to determine immunogenicity before and after primary and secondary vaccinations with 23-valent pneumococcal polysaccharide vaccine in a cohort of 40 elderly patients with chronic lung diseases. Safety of this vaccine was also compared between primary and secondary vaccination. We analyzed serotype-specific immunoglobulin G (IgG) and the opsonization index (OI) for serotypes 6B, 14, 19F, and 23F and compared adverse local and systemic reactions. The levels of serotype-specific IgG and the OIs significantly increased 1 month after primary and secondary vaccinations. Peak levels of IgG after secondary vaccination were 5-20% lower than those after primary vaccination, while serotype-specific OIs after secondary vaccination were comparable with those after primary vaccination. The levels of serotype-specific IgG required for 50% killing significantly decreased 1 month after vaccination. These values for serotypes 14, 19F, and 23F were slightly elevated immediately before secondary vaccination, but those for serotype 6B did not change. After secondary vaccination, these values declined slightly for serotypes 14, 19F, and 23F and remained low for serotype 6B. Although self-limited local and systemic reactions were more frequent after secondary vaccination compared with primary vaccination, no serious systemic reaction was found after either vaccination. Our data suggest a sustained functional serotype-specific IgG after primary and secondary vaccination and confirmed the safety of secondary vaccination among elderly individuals with chronic lung disease.
authors.affiliation: Department of Allergy, National Hospital Organization Tokyo National Hospital, Japan.
authors.forename: Nobuharu
authors.initials: N
authors.lastname: Ohshima
authors.affiliation: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Nagai
authors.affiliation: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Matsui
authors.affiliation: Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Akashi
authors.affiliation: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Makino
authors.affiliation: International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Akeda
authors.affiliation: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan. Electronic address: oishik@nih.go.jp.
authors.forename: Kazunori
authors.initials: K
authors.lastname: Oishi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D000917:Antibody Formation; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D008171:Lung Diseases / Q000276:immunology*; D008297:Male; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines
keywords: Opsonophagocytic activity; Pneumococcal polysaccharide vaccine; Revaccination; Serotype-specific IgG